SEC Form 4 · accession 0001562180-19-000187
Sage Therapeutics, Inc. · SAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Geno J Germano
Director
Period of report
Jan 3, 2019
Accepted (ET)
Jan 4, 2019 · 4:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597553
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $89.33 | Jan 3, 2019 | A | 878 | A | — | Jan 3, 2029 | Common Stock | 878 | 878 | D |
Explanation of responses
- F1The reporting person elected to receive this stock option award in lieu of payment of all cash retainers that would otherwise be paid for his service during 2019 on the issuer's board or its committees, as permitted under the issuer's amended and restated non-employee director compensation policy. The stock option is granted under and subject to the terms of the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. The option will vest in full on December 31, 2019, subject to the reporting person's continued service through such date.